BRPI0510001A - diaminotiazóis substituìdos na piperidina - Google Patents

diaminotiazóis substituìdos na piperidina

Info

Publication number
BRPI0510001A
BRPI0510001A BRPI0510001-1A BRPI0510001A BRPI0510001A BR PI0510001 A BRPI0510001 A BR PI0510001A BR PI0510001 A BRPI0510001 A BR PI0510001A BR PI0510001 A BRPI0510001 A BR PI0510001A
Authority
BR
Brazil
Prior art keywords
treatment
control
diaminothiazoles
piperidine substituted
cancer
Prior art date
Application number
BRPI0510001-1A
Other languages
English (en)
Inventor
Qingjie Ding
Nan Jiang
Kyungjin Kim
Allen John Lovey
Warren William Mccomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0510001A publication Critical patent/BRPI0510001A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

DIAMINOTIAZóIS SUBSTITUìDOS NA PIPERIDINA. A presente invenção refere-se a novos diaminotiazóis de fórmula (I): Estes compostos inibem seletivamente a atividade de Cdk4 e são desse modo, úteis no tratamento ou controle de câncer, em particular, o tratamento ou controle de tumores sólidos. Esta invenção também fornece composições farmacêuticas que contêm tais compostos e métodos de tratar ou controlar câncer, mais particularmente, o tratamento ou controle de tumores de mama, pulmão, cólon, e próstata.
BRPI0510001-1A 2004-04-20 2005-04-08 diaminotiazóis substituìdos na piperidina BRPI0510001A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56371204P 2004-04-20 2004-04-20
PCT/EP2005/003734 WO2005103034A1 (en) 2004-04-20 2005-04-08 Novel piperidine substituted diaminothiazoles

Publications (1)

Publication Number Publication Date
BRPI0510001A true BRPI0510001A (pt) 2007-09-18

Family

ID=34964131

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510001-1A BRPI0510001A (pt) 2004-04-20 2005-04-08 diaminotiazóis substituìdos na piperidina

Country Status (14)

Country Link
US (1) US7211576B2 (pt)
EP (1) EP1740576B1 (pt)
JP (1) JP2007533674A (pt)
KR (1) KR100832280B1 (pt)
CN (1) CN1942464A (pt)
AT (1) ATE435224T1 (pt)
AU (1) AU2005235679A1 (pt)
BR (1) BRPI0510001A (pt)
CA (1) CA2562377A1 (pt)
DE (1) DE602005015203D1 (pt)
ES (1) ES2327248T3 (pt)
MX (1) MXPA06011996A (pt)
RU (1) RU2382784C2 (pt)
WO (1) WO2005103034A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423053B2 (en) * 2004-07-15 2008-09-09 Hoffmann-La Roche Inc. 4-Aminothiazole derivatives
US7705009B2 (en) * 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
US10787410B2 (en) * 2013-12-16 2020-09-29 The Johns Hopkins University Treating and preventing diseases by modulating cell mechanics
WO2017015484A1 (en) * 2015-07-23 2017-01-26 Temple University-Of The Commonwealth System Of Higher Education Novel aminothiazole compounds and methods using same
WO2018136766A1 (en) 2017-01-19 2018-07-26 Temple University-Of The Commonwealth System Of Higher Education Novel bridged bicycloalkyl-substituted aminothizoles and their methods of use
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
CN121219271A (zh) * 2023-05-15 2025-12-26 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的化合物
WO2025128616A1 (en) * 2023-12-12 2025-06-19 Genesis Therapeutics, Inc. Compounds for treating cancer
WO2025167814A1 (zh) * 2024-02-06 2025-08-14 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2714059B1 (fr) * 1993-12-21 1996-03-08 Sanofi Elf Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
KR20000070751A (ko) 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
AU742999B2 (en) 1997-08-20 2002-01-17 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
UA66810C2 (uk) * 1997-10-27 2004-06-15 Агорон Фармацевтикалз Інк. Похідні 4-амінотіазолу та композиції на їх основі як інгібітори циклінозалежних кіназ
US6040321A (en) 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
UA62996C2 (en) 1998-02-26 2004-01-15 Aventic Pharmaceuticals Inc 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines
US6479487B1 (en) 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
GB9823871D0 (en) 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
WO2001056567A1 (en) 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
BR0113139A (pt) 2000-08-09 2003-06-24 Agouron Pharma Compostos, seus sais, formas multiméricas, pró-drogas ou metabólitos, composições farmacêuticas, método de tratamento de uma doença ou disfunção mediana através da inibição de cdk4 ou um complexo de cdk4/ciclina, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase e método de modulação ou inibição da atividade de um receptor de proteìna cinase
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
US6818663B2 (en) 2002-05-17 2004-11-16 Hoffmann-La Roches Diaminothiazoles
WO2004014904A1 (en) 2002-08-09 2004-02-19 Pfizer Inc. Antiproliferative 2-(heteroaryl)-aminothiazole compounds, pharmaceutical compositions and methods for their use
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives

Also Published As

Publication number Publication date
CN1942464A (zh) 2007-04-04
RU2006140862A (ru) 2008-05-27
KR100832280B1 (ko) 2008-05-26
ES2327248T3 (es) 2009-10-27
WO2005103034A8 (en) 2006-11-02
WO2005103034A1 (en) 2005-11-03
AU2005235679A1 (en) 2005-11-03
ATE435224T1 (de) 2009-07-15
KR20060135905A (ko) 2006-12-29
RU2382784C2 (ru) 2010-02-27
CA2562377A1 (en) 2005-11-03
MXPA06011996A (es) 2007-04-24
US20050239843A1 (en) 2005-10-27
DE602005015203D1 (de) 2009-08-13
EP1740576A1 (en) 2007-01-10
EP1740576B1 (en) 2009-07-01
US7211576B2 (en) 2007-05-01
JP2007533674A (ja) 2007-11-22

Similar Documents

Publication Publication Date Title
BRPI0511975A (pt) pirazolopirimidinas
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
BRPI0409366A (pt) compostos de pirimido
BR0206496A (pt) Diaminotiazóis
BRPI0412820A (pt) compostos de aminopirazol e utilização como inibidores de chk1
BRPI0518152A (pt) pirazolbenzodiazepinas dissubstituìdas úteis como inibidores para cdk2 e angiogênese e para o tratamento de cánceres de mama, cólon, pulmão e próstata
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
MX2009010034A (es) Pirimidodiazepinas sustituidas utiles inhibidores de la plk1.
BRPI0515577A (pt) compostos de carbonila que podem ser empregados como inibidores de fator xa de coagulação
BRPI0414908A (pt) compostos de benzazóis substituìdos, composições e métodos de inibição da atividade raf quinase em um humano ou animal
BR0317480A (pt) Derivados de piridino[2,3-d]pirimidina como inibidores kdr e fgfr seletivos
MX2009004699A (es) Compuestos de piridinona.
BRPI0511132A (pt) derivados de pirimidina e composição farmacêutica compreendendo os mesmos
BRPI0513836A (pt) composto, métodos de tratar, controlar ou prevenir cáncer, uma doença associada com angiogênese indesejada, e uma doença ou distúrbio mediado por pde 4, e de reduzir ou inibir o nìvel ou a atividade de pde 4 em um paciente, e, composição farmacêutica
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
TNSN08020A1 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
BRPI0410238A (pt) compostos orgánicos
BRPI0408444A (pt) derivados de 1-n-(fenil)-2-n-(fenil) pirazolidina-1,2-dicarboxamida como inibidores de fator xa de coagulação para o tratamento de trombose
BRPI0409263A (pt) composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita
BRPI0513278A (pt) uso de um composto, composto, composição farmacêutica, processo para produzir um composto, e, método para causar a morte celular através de terapia de ativação por fóton
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3
BR0309988A (pt) Composto, composição farmacêutica, métodos para tratar ou melhorar doenças ou condições proliferativas e doenças inflamatórias, e, uso de um composto
WO2005103034A8 (en) Novel piperidine substituted diaminothiazoles
BRPI0513366A (pt) derivados de 2,6-diaminopiridina-3-ona

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.